Medpace Holdings, Inc. — Q3 2020 Form 10-Q
Business context and period: Medpace provides global, full-service clinical research and development services to pharmaceutical, biotechnology, and medical-device companies. This unaudited filing covers the quarter and nine months ended September 30, 2020; comparisons are to the corresponding 2019 periods.
Financial performance
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $230.4 million | $216.2 million | $666.2 million | $631.1 million |
| Operating income | $46.4 million | $30.0 million | $112.1 million | $91.1 million |
| Operating margin | 20.1% | 13.9% | 16.8% | 14.4% |
| Net income | $41.5 million | $24.0 million | $94.5 million | $70.6 million |
| Diluted EPS | $1.09 | $0.63 | $2.50 | $1.88 |
| Operating cash flow | — | $153.2 million | $144.9 million |
- Q3 revenue grew 6.5%; nine-month revenue grew 5.6%. Management attributed growth mainly to Oncology, Cardiology, AVAI, and other therapeutic areas.
- Q3 operating income rose 54.8%, with operating margin improving to 20.1%. SG&A fell 21.7% to $22.8 million; direct costs increased 2.7% to $156.2 million.
- Nine-month capital expenditures were $23.6 million, compared with $12.2 million in 2019. Cash from operations less property and equipment expenditures was approximately $129.6 million.
- Cash and cash equivalents were $219.2 million at September 30, up from $131.9 million at year-end 2019. Current assets were $395.0 million and current liabilities $358.4 million.
- No borrowings were outstanding under the $50 million revolving credit facility; $49.8 million was available and $0.2 million of letters of credit was outstanding. The facility expires March 31, 2021.
- Operating lease liabilities totaled $125.8 million. These are lease obligations, not reported funded debt.
Material changes and operating metrics
- Net new business awards were $315.4 million in Q3 and $816.4 million for the first nine months, versus $285.4 million and $813.3 million, respectively, in 2019.
- Backlog was $1.434 billion at September 30, up 16.7% from $1.229 billion a year earlier. Approximately $710–$730 million was expected to convert to revenue over the next 12 months. Management cautioned that backlog and awards may not reliably predict future revenue.
- Share repurchases totaled $50.8 million for the first nine months (772,125 shares); none occurred in Q3. A further $49.2 million remained authorized.
- Cash flow from operations increased, while investing cash outflow rose to $23.5 million. Financing cash outflow was $42.1 million, primarily reflecting repurchases; the prior-year period included $80.4 million of debt repayment.
Outlook, risks, and unusual items
- COVID-19: Management said the pandemic had significantly adversely affected the first three quarters and expected continued adverse effects, potentially material, though the duration and financial impact could not be reasonably estimated. Site disruption, reduced trial starts, slower awards and patient recruitment, possible cancellations, and funding constraints among smaller clients were identified risks. The company used alternatives such as virtual monitoring and made staff reductions in some geographies.
- No specific revenue or earnings guidance was provided. Management described plans to fund organic growth, capital spending, and selective bolt-on acquisitions from cash and operating cash flow, with borrowing available if needed.
- Legal proceedings and potential losses were described as immaterial. The company disclosed $10.2 million of minimum project-supply purchase commitments, expiring through 2026.
- Related-party arrangements include leases of company facilities from entities owned by the CEO and family members, and executive-related travel services. The company began occupying additional CEO-related leased headquarters space in Q2 2020; related-party lease obligations are included in total lease liabilities.
- The effective tax rate declined to 11.8% in Q3 and 17.0% for the first nine months, primarily reflecting share-based compensation tax benefits and FDII benefits. Management reported no material changes to previously disclosed risk factors apart from the COVID-19 discussion.
Important facts for investors to verify
- Whether COVID-19-related trial delays, reduced starts, recruitment difficulties, or client funding pressures affect cancellations, revenue conversion, and margins.
- Backlog conversion and the timing of the stated $710–$730 million expected to convert within 12 months; backlog is not a guarantee of revenue.
- The extent to which Q3 margin improvement reflects sustainable operating efficiencies versus timing, expense reductions, or other period-specific factors.
- Cash use for repurchases and capital investment, and the status and renewal or replacement of the credit facility due March 31, 2021.
- Terms, governance, and ongoing costs of related-party leases, given the $125.8 million total operating lease liability.